These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 7659482)

  • 1. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines.
    Pichichero ME; Christy C; Decker MD; Steinhoff MC; Edwards KM; Rennels MB; Anderson EL; Englund JA
    Pediatrics; 1995 Sep; 96(3 Pt 2):588-92. PubMed ID: 7659482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations.
    Deloria MA; Blackwelder WC; Decker MD; Englund JA; Steinhoff MC; Pichichero ME; Rennels MB; Anderson EL; Edwards KM
    Pediatrics; 1995 Sep; 96(3 Pt 2):592-4. PubMed ID: 7659483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 13 acellular pertussis vaccines: adverse reactions.
    Decker MD; Edwards KM; Steinhoff MC; Rennels MB; Pichichero ME; Englund JA; Anderson EL; Deloria MA; Reed GF
    Pediatrics; 1995 Sep; 96(3 Pt 2):557-66. PubMed ID: 7659476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DTP vaccine reactions: effect of prior reactions on rate of subsequent reactions.
    Baraff LJ; Cherry JD; Cody CL; Marcy SM; Manclark CR
    Dev Biol Stand; 1985; 61():423-8. PubMed ID: 3879687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine.
    Scheifele DW; Bjornson G; Halperin SH; Mitchell L; Boraston S
    CMAJ; 1994 Jan; 150(1):29-35. PubMed ID: 8275406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
    Rennels MB; Reed GF; Decker MD; Edwards KM; Pichichero ME; Deloria MA; Englund JA; Anderson EL; Steinhoff MC; Deforest A
    Pediatrics; 1995 Sep; 96(3 Pt 2):576-9. PubMed ID: 7659479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
    Taranger J; Trollfors B; Knutsson N
    Dev Biol Stand; 1997; 89():109-12. PubMed ID: 9272340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
    Feldman S; Perry CS; Andrew M; Jones L; Moffitt JE; Lamb D; Meschievitz C
    South Med J; 1993 Mar; 86(3):269-75, 284. PubMed ID: 8451663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants.
    Shek LP; Khor ES; Tan GH; Low KT; Ong D; Roy J; Han HH; Bock HL; Lee BW
    Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):863-8. PubMed ID: 15115101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetaminophen and ibuprofen for prevention of adverse reactions associated with childhood immunization.
    Manley J; Taddio A
    Ann Pharmacother; 2007 Jul; 41(7):1227-32. PubMed ID: 17519301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.